Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Revelation Biosciences ( (REVB) ).
On January 23, 2026, Revelation Biosciences entered into inducement agreements with two holders of its existing Class I common stock warrants, leading to the immediate cash exercise of 8,544,999 pre-split (2,136,251 post-split) warrants at an effective post-split price of $3.44 per share, generating approximately $7.3 million in gross proceeds to support its clinical development plans, working capital and general corporate needs. In return, the company issued 17,089,998 pre-split (4,272,500 post-split) new Class J common stock warrants in a private placement exempt from registration, with the new warrants becoming exercisable for five years following stockholder approval, while Revelation agreed to file a resale registration statement for the underlying shares and pay Roth Capital Partners an 8% advisory fee; the company also clarified that an initially expected third investor ultimately withdrew, reducing the originally anticipated size of the transaction.
The most recent analyst rating on (REVB) stock is a Hold with a $0.51 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.
Spark’s Take on REVB Stock
According to Spark, TipRanks’ AI Analyst, REVB is a Neutral.
The score is primarily held down by very weak financial performance (no revenue, ongoing losses, and significant cash burn) and bearish technicals (price well below major moving averages with negative momentum). A positive clinical development update provides some support, but valuation remains constrained by unprofitability and no dividend.
To see Spark’s full report on REVB stock, click here.
More about Revelation Biosciences
Revelation Biosciences, Inc. is a clinical-stage biotechnology company focused on advancing clinical development programs, using capital raises to fund working capital and general corporate purposes as it progresses its pipeline.
Average Trading Volume: 555,080
Technical Sentiment Signal: Sell
Current Market Cap: $13.25M
For a thorough assessment of REVB stock, go to TipRanks’ Stock Analysis page.